CARLSBAD, Calif., Oct. 14 /PRNewswire/ -- GenVault Corporation today announces that Mr. Mark Sutherland has joined GenVault as its Senior Vice President of Business Development. Mr. Sutherland will be responsible for finding, prioritizing and closing significant opportunities for partnering and licensing the company's products and technologies as well as developing a series of strategic alliances.
Mr. Sutherland has more than 25 years experience in life sciences business development, sales and marketing. Mr. Sutherland comes to GenVault from the Discovery Systems business unit of GE Healthcare where he served as its VP, Strategic Alliances. Prior to GE Healthcare, Mr. Sutherland spent 6 years at Amersham Biosciences as VP, Strategic Alliances and previously as VP, Genomics, where he led a $160M genomics business unit producing industry leading technologies in DNA sequencing, genotyping and gene expression. Mr. Sutherland has also held roles of increasing responsibility in sales and marketing management at Molecular Dynamics and Applied Biosystems during phases of unprecedented growth for each company. Mr. Sutherland holds a bachelor of science with honors in Chemistry from Stanford University.
"Mark's great wealth of experience in the life sciences arena will be a very positive asset for GenVault," said David Wellis, GenVault President and CEO. "Mark also brings deep relationships with a number of the companies we are looking to do business with in the coming years. In addition, Mark will be helping us refine our strategic plans as an active member of the senior management team."
GenVault is the global leader in providing biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. Today, GenVault is empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies to more fully leverage the rapidly growing genomics industry. As a scalable and reliable alternative to traditional freezers and DNA purification systems, the company's dry-state platform enables the extraction, preservation, recovery, and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. From GenPlate to the Dynamic Archive, GenVault is continuously developing and refining best practices for DNA sample management and preservation. For more information visit GenVault at http://www.genvault.com.
CONTACT: David Wellis, CEO of GenVault Corporation, +1-760-268-5256
Web site: http://www.genvault.com/